Maven Securities LTD Purchases Shares of 400,000 Roivant Sciences Ltd. (NASDAQ:ROIV)

Maven Securities LTD bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm bought 400,000 shares of the company's stock, valued at approximately $4,616,000. Maven Securities LTD owned about 0.05% of Roivant Sciences at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Integrated Wealth Concepts LLC grew its stake in Roivant Sciences by 3.9% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 246,537 shares of the company's stock valued at $2,845,000 after buying an additional 9,164 shares during the last quarter. TOMS Capital Investment Management LP acquired a new position in Roivant Sciences in the 3rd quarter valued at $46,333,000. Erste Asset Management GmbH acquired a new position in Roivant Sciences in the 3rd quarter valued at $2,457,000. Edgestream Partners L.P. bought a new stake in Roivant Sciences in the 3rd quarter valued at $557,000. Finally, PDT Partners LLC boosted its holdings in Roivant Sciences by 116.8% in the 3rd quarter. PDT Partners LLC now owns 399,107 shares of the company's stock valued at $4,606,000 after purchasing an additional 215,000 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Roivant Sciences

In other news, CEO Matthew Gline sold 1,983,257 shares of Roivant Sciences stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the completion of the sale, the chief executive officer now owns 17,870,543 shares in the company, valued at $210,693,701.97. The trade was a 9.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Rakhi Kumar sold 250,000 shares of Roivant Sciences stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $11.89, for a total transaction of $2,972,500.00. Following the sale, the chief accounting officer now owns 209,322 shares of the company's stock, valued at approximately $2,488,838.58. This represents a 54.43 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,677,309 shares of company stock worth $43,283,184. 7.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on ROIV. HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. Bank of America increased their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a "neutral" rating in a report on Wednesday, September 11th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Roivant Sciences in a report on Thursday, September 19th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $17.93.

Roivant Sciences Trading Down 0.1 %

ROIV stock traded down $0.01 during trading on Wednesday, hitting $12.11. 6,446,554 shares of the stock traded hands, compared to its average volume of 5,814,928. Roivant Sciences Ltd. has a one year low of $9.48 and a one year high of $13.06. The stock has a market cap of $8.82 billion, a price-to-earnings ratio of 2.15 and a beta of 1.25. The company has a 50 day simple moving average of $11.78 and a 200 day simple moving average of $11.39.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.